Tina Kianfar, Raquibul Hasan, Yaser Azizi, Fatemeh Ramezani
{"title":"达帕格列净对心肌缺血动物模型心功能的影响,系统综述与 Meta 分析","authors":"Tina Kianfar, Raquibul Hasan, Yaser Azizi, Fatemeh Ramezani","doi":"10.2174/0127724328313815240723044625","DOIUrl":null,"url":null,"abstract":"\n\nIn this study, a meta-analysis was conducted to investigate the therapeutic\neffect of Dapagliflozin (DAPA) on animals suffering from myocardial ischemia reperfusion compared to the group that did not receive treatment.\n\n\n\nAccording to the inclusion and exclusion criteria two researchers performed the primary\nand secondary screening based on the title abstract and full text. After data extraction, meta-analysis\nwas performed using STATA software. Standardized mean differences were used to analyze the results of the reported studies. Subgroup analysis and quality control of articles were also conducted\n\n\n\nA total of 21 separate experiments showed that DAPA increased mean fractional shortening (%FS) and ejection fraction (%EF) compared to the untreated animals. A significant reduction\nin the weight and size of the infarcted area and significant increases in dp/dt+\n, dp/dt-\n, left ventricular\nend-systolic internal dimensions (LVIDs), left ventricular end-diastolic internal dimensions\n(LVIDd), Volume systole and Volume diastole were observed in treated animals.\n\n\n\nDAPA has the potential to become a candidate for the treatment of post-ischemic heart\ndamage, pending animal and human studies to validate this.\n","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect of Dapagliflozin on Heart Function in Animal Models of\\nCardiac Ischemia, A Systematic Review and Meta-analysis\",\"authors\":\"Tina Kianfar, Raquibul Hasan, Yaser Azizi, Fatemeh Ramezani\",\"doi\":\"10.2174/0127724328313815240723044625\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nIn this study, a meta-analysis was conducted to investigate the therapeutic\\neffect of Dapagliflozin (DAPA) on animals suffering from myocardial ischemia reperfusion compared to the group that did not receive treatment.\\n\\n\\n\\nAccording to the inclusion and exclusion criteria two researchers performed the primary\\nand secondary screening based on the title abstract and full text. After data extraction, meta-analysis\\nwas performed using STATA software. Standardized mean differences were used to analyze the results of the reported studies. Subgroup analysis and quality control of articles were also conducted\\n\\n\\n\\nA total of 21 separate experiments showed that DAPA increased mean fractional shortening (%FS) and ejection fraction (%EF) compared to the untreated animals. A significant reduction\\nin the weight and size of the infarcted area and significant increases in dp/dt+\\n, dp/dt-\\n, left ventricular\\nend-systolic internal dimensions (LVIDs), left ventricular end-diastolic internal dimensions\\n(LVIDd), Volume systole and Volume diastole were observed in treated animals.\\n\\n\\n\\nDAPA has the potential to become a candidate for the treatment of post-ischemic heart\\ndamage, pending animal and human studies to validate this.\\n\",\"PeriodicalId\":29871,\"journal\":{\"name\":\"Current Reviews in Clinical and Experimental Pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Reviews in Clinical and Experimental Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0127724328313815240723044625\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Reviews in Clinical and Experimental Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127724328313815240723044625","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
根据纳入和排除标准,两名研究人员根据标题摘要和全文进行了初筛和复筛。提取数据后,使用 STATA 软件进行荟萃分析。使用标准化平均差来分析报告的研究结果。共有 21 项单独的实验表明,与未经处理的动物相比,DAPA 增加了平均骨折缩短率(%FS)和射血分数(%EF)。在接受治疗的动物身上,可以观察到梗死区的重量和大小明显减少,dp/dt+、dp/dt-、左心室收缩末期内径(LVIDs)、左心室舒张末期内径(LVIDd)、收缩容积和舒张容积明显增加。
The Effect of Dapagliflozin on Heart Function in Animal Models of
Cardiac Ischemia, A Systematic Review and Meta-analysis
In this study, a meta-analysis was conducted to investigate the therapeutic
effect of Dapagliflozin (DAPA) on animals suffering from myocardial ischemia reperfusion compared to the group that did not receive treatment.
According to the inclusion and exclusion criteria two researchers performed the primary
and secondary screening based on the title abstract and full text. After data extraction, meta-analysis
was performed using STATA software. Standardized mean differences were used to analyze the results of the reported studies. Subgroup analysis and quality control of articles were also conducted
A total of 21 separate experiments showed that DAPA increased mean fractional shortening (%FS) and ejection fraction (%EF) compared to the untreated animals. A significant reduction
in the weight and size of the infarcted area and significant increases in dp/dt+
, dp/dt-
, left ventricular
end-systolic internal dimensions (LVIDs), left ventricular end-diastolic internal dimensions
(LVIDd), Volume systole and Volume diastole were observed in treated animals.
DAPA has the potential to become a candidate for the treatment of post-ischemic heart
damage, pending animal and human studies to validate this.